List of Contents

Non-Oncology Precision Medicine Market Size, Share, and Trends 2024 to 2034

Non-Oncology Precision Medicine Market (By Product: Diagnostics, Therapeutics; By Application: Oncology, CNS, Immunology, Respiratory, Infectious Diseases, Neurology, Others; By End-use: Hospitals, Diagnostic Centers, Research & Academic Institutes, Others; By Ecosystem: Applied Sciences, Precision Diagnostics, Precision Therapeutics, Digital Health and Information Technology) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2034

  • Last Updated : September 2023
  • Report Code : 1798
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-Oncology Precision Medicine Market 

5.1. COVID-19 Landscape: Non-Oncology Precision Medicine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-Oncology Precision Medicine Market, By Product Type

8.1. Non-Oncology Precision Medicine Market, by Product Type, 2023-2032

8.1.1. Diagnostics

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Therapeutics

8.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Non-Oncology Precision Medicine Market, By Application

9.1. Non-Oncology Precision Medicine Market, by Application e, 2023-2032

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. CNS

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Immunology

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Respiratory

9.1.4.1. Market Revenue and Forecast (2021-2034)

9.1.5. Infectious Diseases

9.1.5.1. Market Revenue and Forecast (2021-2034)

9.1.6. Neurology

9.1.6.1. Market Revenue and Forecast (2021-2034)

9.1.7. Cardiovascular

9.1.7.1. Market Revenue and Forecast (2021-2034)

9.1.8. Lifestyle and Endocrinology

9.1.8.1. Market Revenue and Forecast (2021-2034)

9.1.9. Gastroenterology

9.1.9.1. Market Revenue and Forecast (2021-2034)

9.1.10. Others

9.1.10.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Non-Oncology Precision Medicine Market, By End-use 

10.1. Non-Oncology Precision Medicine Market, by End-use, 2023-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Diagnostic Centers

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Research & Academic Institutes

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Non-Oncology Precision Medicine Market, By Ecosystem 

11.1. Non-Oncology Precision Medicine Market, by Ecosystem, 2023-2032

11.1.1. Applied Sciences

11.1.1.1. Market Revenue and Forecast (2021-2034)

11.1.2. Precision Diagnostics

11.1.2.1. Market Revenue and Forecast (2021-2034)

11.1.3. Digital Health and Information Technology

11.1.3.1. Market Revenue and Forecast (2021-2034)

11.1.4. Precision Therapeutics

11.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 12. Global Non-Oncology Precision Medicine Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.1.2. Market Revenue and Forecast, by Application (2021-2034)

12.1.3. Market Revenue and Forecast, by End-use (2021-2034)

12.1.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.1.5.2. Market Revenue and Forecast, by Application (2021-2034)

12.1.5.3. Market Revenue and Forecast, by End-use (2021-2034)

12.1.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.1.6.2. Market Revenue and Forecast, by Application (2021-2034)

12.1.6.3. Market Revenue and Forecast, by End-use (2021-2034)

12.1.6.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.2.2. Market Revenue and Forecast, by Application (2021-2034)

12.2.3. Market Revenue and Forecast, by End-use (2021-2034)

12.2.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.2.5.2. Market Revenue and Forecast, by Application (2021-2034)

12.2.5.3. Market Revenue and Forecast, by End-use (2021-2034)

12.2.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.2.6.2. Market Revenue and Forecast, by Application (2021-2034)

12.2.6.3. Market Revenue and Forecast, by End-use (2021-2034)

12.2.6.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.2.7.2. Market Revenue and Forecast, by Application (2021-2034)

12.2.7.3. Market Revenue and Forecast, by End-use (2021-2034)

12.2.7.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.2.8.2. Market Revenue and Forecast, by Application (2021-2034)

12.2.8.3. Market Revenue and Forecast, by End-use (2021-2034)

12.2.8.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.3.2. Market Revenue and Forecast, by Application (2021-2034)

12.3.3. Market Revenue and Forecast, by End-use (2021-2034)

12.3.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.3.5.2. Market Revenue and Forecast, by Application (2021-2034)

12.3.5.3. Market Revenue and Forecast, by End-use (2021-2034)

12.3.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.3.6.2. Market Revenue and Forecast, by Application (2021-2034)

12.3.6.3. Market Revenue and Forecast, by End-use (2021-2034)

12.3.6.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.3.7.2. Market Revenue and Forecast, by Application (2021-2034)

12.3.7.3. Market Revenue and Forecast, by End-use (2021-2034)

12.3.7.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.3.8.2. Market Revenue and Forecast, by Application (2021-2034)

12.3.8.3. Market Revenue and Forecast, by End-use (2021-2034)

12.3.8.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.4.2. Market Revenue and Forecast, by Application (2021-2034)

12.4.3. Market Revenue and Forecast, by End-use (2021-2034)

12.4.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.4.5.2. Market Revenue and Forecast, by Application (2021-2034)

12.4.5.3. Market Revenue and Forecast, by End-use (2021-2034)

12.4.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.4.6.2. Market Revenue and Forecast, by Application (2021-2034)

12.4.6.3. Market Revenue and Forecast, by End-use (2021-2034)

12.4.6.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.4.7.2. Market Revenue and Forecast, by Application (2021-2034)

12.4.7.3. Market Revenue and Forecast, by End-use (2021-2034)

12.4.7.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.4.8.2. Market Revenue and Forecast, by Application (2021-2034)

12.4.8.3. Market Revenue and Forecast, by End-use (2021-2034)

12.4.8.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.5.2. Market Revenue and Forecast, by Application (2021-2034)

12.5.3. Market Revenue and Forecast, by End-use (2021-2034)

12.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.5.5.2. Market Revenue and Forecast, by Application (2021-2034)

12.5.5.3. Market Revenue and Forecast, by End-use (2021-2034)

12.5.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product Type (2021-2034)

12.5.6.2. Market Revenue and Forecast, by Application (2021-2034)

12.5.6.3. Market Revenue and Forecast, by End-use (2021-2034)

12.5.6.4. Market Revenue and Forecast, by Ecosystem (2021-2034)

Chapter 13. Company Profiles

13.1. Pfizer Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Qiagen Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Quest Diagnostics Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Medtronic

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Novartis

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Laboratory Corporation of America Holdings

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. bioMérieux SA

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Abbott Laboratories

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. F. Hoffmann-La Roche A

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Eli Lilly & Company

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client